Valuation
- Market cap
- 124,000
- Revenue TTM
- $3,800,000
- Net income TTM
- $-11,420,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -300.53%
- Debt to equity
- -0.12
Trading
- Volume
- 900
- Avg volume
- —
- Day's range
- $0.01 – $0.01
- Shares out
- 123,553,000
- Stochastic %K
- —
- Beta
- -4.21
- Analysts
- —
- Price target
- —
Company profile
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The c...
Show more
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company's lead product is Aristotle, a mRNA-based multi-cancer detection panel that tests blood for multiple discrete cancer. It also offers ColonSentry, a blood-based test to determine an individual's current risk for having colorectal cancer. The company is based in Richmond Hill, Canada.
- Industry
- Diagnostics & Research
- Sector
- Healthcare
- Website
- https://www.stagezerolifesciences.com
- Address
- 70 East Beaver Creek Road, Unit 30, Richmond Hill, Canada
Latest news
No headlines yet.
